Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round
PR88701
CINCINNATI, March 26, 2021 /PRNewswire=KYODO JBN/ --
Amplicore Inc. (
) , an early-stage biopharmaceutical company currently developing locally
delivered and minimally invasive therapeutic solutions for musculoskeletal
diseases, has successfully closed its Series Seed round of funding at $4
million. Investments were led by Photon Fund, with participation from
Industrial Technology Investment Corporation, Berkeley Catalyst Fund, and SVE
Capital.
Photo - https://mma.prnewswire.com/media/1474462/Amplicore_headshot.jpg
Logo - https://mma.prnewswire.com/media/1474463/Amplicore_Logo.jpg
"We are very pleased to have accomplished this important milestone and to have
such an eminent group of investors supporting our science and vision," stated
Dr. Chia-Ying (James) Lin, Founder, President, and CEO. "These proceeds will
enable Amplicore to complete the preclinical development of its two leading
products, AM3101 and AM1101, and position the company for the next round of
financing."
Amplicore is also leveraging a study on the healing of acute meniscal tear
after surgical repair, supported by a grant from the US Department of Defense
(DoD). Meniscal tears are among the most common knee injuries and are
frequently associated with sports and military injuries to the knee joint. Much
of the meniscus is avascular tissue, and the limited blood supply to this area
impedes the healing process, resulting in a surgical failure rate of ~25%.
Amplicore's technology has demonstrated promising pre-clinical results as a
potential minimally invasive and regenerative approach to managing soft tissue
injury.
The company is also developing AM1101 as a treatment for osteoarthritis (OA)
designed to reduce joint OA pain, inhibit cartilage degradation, and promote
tissue regeneration of the aberrant cartilage associated with the disease.
AM1101 addresses a large unmet medical need in the treatment OA, a debilitating
and degenerative musculoskeletal disease.
About Amplicore, Inc.
Amplicore, Inc. is an early-stage startup Biotech company based on technology
developed in the laboratories of Dr. Chia-Ying James Lin, the company's
founder, at the University of Cincinnati. Headquartered in Mason, OH, the
company is dedicated to developing novel injectable therapeutics to serve unmet
medical needs of degenerative musculoskeletal disorders. Unlike current
therapies that focus on the palliative treatment of these disorders, Amplicore
is taking a regenerative approach to treat joint osteoarthritis, cartilage
damage, degenerative disc disease, and acute meniscus tear. The company's lead
products AM3101 and AM1101 address significant deficiencies in the current
standard of care for the treatment of acute meniscal tear and OA, respectively.
Our mission is to translate scientific innovation into effective but minimally
invasive products that can be easily delivered to patients.
SOURCE Amplicore, Inc.
CONTACT: info@amplicorepharma.com.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
